Efficacy of Omalizumab against Aspirin-hypersensitivity and Overproduction of Cysteinyl Leukotrienes in Aspirin-exacerbated Respiratory Disease: A Randomized Trial - 01/02/21
Doi : 10.1016/j.jaci.2020.12.226
Hiroaki Hayashi, MD 1, Yuma Fukutomi, MD 2, Chihiro Mitsui, MD 2, Keiichi Kajiwara, BSc 2, Kentaro Watai 2, Yosuke Kamide, MD PhD 2, Maki Iwata, MD 2, Kisako Nagayama 2, Yuto Nakamura, MD 2, Yuto Hamada 2, Yasuhiro Tomita, MD PhD 1, Kiyoshi Sekiya 2, Takahiro Tsuburai, MD PhD 3, Akio Mori, MD PhD 2, Kenji Izuhara 4, Keiko Wakahara, MD PhD 5, Naozumi Hashimoto, MD PhD 5, Yoshinori Hasegawa, MD PhD 5, Masami Taniguchi, MD, PhD 6
1 Clinical Research Center, National Hospital Organization Sagamihara National Hospital and Department of Respiratory Medicine, Nagoya University Graduate School of Medicine
2 National Hospital Organization Sagamihara National Hospital
3 St. Marianna University School of Medicine
4 Saga Medical School
5 Nagoya University Graduate School of Medicine
6 Clinical Research Center, National Hospital Organization Sagamihara National Hospital and Shonan Kamakura General Hospital Center for Immunology and Allergology
172
Le texte complet de cet article est disponible en PDF.Plan
© 2020
Publié par Elsevier Masson SAS.
Vol 147 - N° 2S
P. AB56 - février 2021 Retour au numéro
Article précédent
- Steroid Stewardship – Survey Results & Awareness Strategies
- Jackie Eghrari-Sabet, Tonya Winders
- Managing Patients with Severe Asthma and Common Comorbidities of Atopy, Obesity & Depression/Anxiety: Real-world Effectiveness of Mepolizumab
- Nestor Molfino, Thomas Casale, Jared Silver, Michael Bogart, Elizabeth Packnett, Donna McMorrow, Juan Wu, Beth Hahn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?